Ionis Pharmaceuticals Inc
(NAS:IONS)
$
35.91
-0.42 (-1.16%)
Market Cap: 5.74 Bil
Enterprise Value: 4.73 Bil
PE Ratio: 0
PB Ratio: 8.65
GF Score: 40/100 Ionis Pharmaceuticals Inc at Wells Fargo Healthcare Conference Transcript
Sep 07, 2022 / 03:00PM GMT
Release Date Price:
$43.45
(+4.32%)
Yanan Zhu
Wells Fargo Securities, LLC, Research Division - Senior Equity Analyst
Okay. So thanks, everyone, for joining us. I think we should get started. We are very fortunate here to have the team from Ionis presenting at our conference. My name is Yanan, and with us today here are Brett Monia, CEO of Ionis; and Eugene Schneider, the Chief Clinical Development Officer at Ionis. So Brett and Eugene, thank you for being with us.
Brett P. Monia
Ionis Pharmaceuticals, Inc. - Founder, CEO & Director
Thank you. Thanks for having us.
Questions & Answers
Yanan Zhu
Wells Fargo Securities, LLC, Research Division - Senior Equity Analyst
So this morning, actually, the company reported the Phase III data for eplontersen in ATTR cardiomyopathy at the IFA conference in Germany. Would you -- could you walk us through the data and tell us why you're so excited about the eplontersen program?
Brett P. Monia
Ionis Pharmaceuticals, Inc. - Founder, CEO & Director
Happy
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot